DIGESTIVE DRUGS MARKET ANALYSIS

Digestive Drugs Market, By Type (Branded and Generic), By Drug Class (5-aminosalicylates, GI stimulants, Laxatives, Antacids, H2 Antagonists, Antidiarrheals, Others), By Route of Administration (Oral, Intravenous, Others), By Application (Gastroesophageal Reflux Disease (GERD), Irritable Bowel Syndrome, Ulcerative Colitis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Feb 2023
Code : CMI5542
Pages :250
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Key players operating in the market are getting approval to new digestive drugs, which is expected to drive the global digestive drugs market growth during the forecast period.

The approval of new therapeutic solutions for gastrointestinal disorders is further contributing to the market growth. For instance, in March 2020, Cipla received the U.S. Food and Drug Administration (FDA) approval for a generic acid reflux drug. The company received final approval for generic Esomeprazole, an oral suspension which is used for treatment of gastroesophageal reflux disease. Esomeprazole is available for various strengths such as 10mg, 20 mg and 40 mg from the U.S. Food and Drug Administration (U.S. FDA).

Key Players

Major players operating in the global digestive drugs market include GlaxoSmithKline plc, AbbVie Inc. (Allergan), Takeda Pharmaceutical Company Limited, Pfizer Inc, AstraZeneca plc, Marksans Pharma, Tillotts Pharma AG, Salix Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Merck & Co., Inc., Lexicon Pharmaceuticals, Inc., Bayer AG, Cadila Healthcare Ltd.